A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

This study tests CM326, an investigational drug, in people with moderate to severe COPD (chronic obstructive pulmonary disease — a lung condition that makes breathing difficult). The goal is to see if CM326 is safe and can improve lung function and reduce flare-ups. **You may be eligible if...** - You are 40 to 85 years old and weigh at least 40 kg - You have been diagnosed with COPD for at least 12 months - Your lung function tests confirm moderate-to-severe COPD (specific spirometry criteria) - You have been on stable COPD medication for at least 3 months **You may NOT be eligible if...** - You have a recent COPD exacerbation or serious infection - You have other significant lung or heart conditions - You are outside the age or weight range Talk to your doctor to see if this trial is right for you.